Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.778,03
0,58%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ XOMA Corporation (XOMA) XOMA Corporation (XOMA) Notizie

XOMA

XOMA (XOMA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XOMA
DataOraFonteTitoloSimboloCompagnia
25/04/202413:30GlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Corporation
24/04/202415:00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:XOMAXOMA Corporation
03/04/202415:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAXOMA Corporation
21/03/202412:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Corporation
19/03/202421:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAXOMA Corporation
08/03/202413:30GlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Corporation
28/02/202413:30GlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAXOMA Corporation
16/02/202414:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAXOMA Corporation
18/01/202414:30GlobeNewswire Inc.XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionNASDAQ:XOMAXOMA Corporation
11/01/202422:50Dow Jones NewsXoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolNASDAQ:XOMAXOMA Corporation
11/01/202422:05GlobeNewswire Inc.FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxNASDAQ:XOMAXOMA Corporation
08/01/202413:30GlobeNewswire Inc.XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsNASDAQ:XOMAXOMA Corporation
02/01/202413:30GlobeNewswire Inc.XOMA Announces Stock Repurchase Program of up to $50 MillionNASDAQ:XOMAXOMA Corporation
19/12/202313:30GlobeNewswire Inc.XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesNASDAQ:XOMAXOMA Corporation
07/11/202313:30GlobeNewswire Inc.XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Corporation
31/10/202312:30GlobeNewswire Inc.XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Corporation
06/09/202313:30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:XOMAXOMA Corporation
08/08/202313:30GlobeNewswire Inc.XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyNASDAQ:XOMAXOMA Corporation
24/06/202300:14GlobeNewswire Inc.XOMA Added to the Russell 2000® and Russell 3000® IndexesNASDAQ:XOMAXOMA Corporation
22/06/202313:30GlobeNewswire Inc.XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology AssetNASDAQ:XOMAXOMA Corporation
25/05/202322:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAXOMA Corporation
18/05/202323:23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XOMAXOMA Corporation
09/05/202313:36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XOMAXOMA Corporation
09/05/202313:30GlobeNewswire Inc.XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization StrategyNASDAQ:XOMAXOMA Corporation
26/04/202313:30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright BioConnect Investor ConferenceNASDAQ:XOMAXOMA Corporation
04/04/202322:20Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XOMAXOMA Corporation
30/03/202313:30GlobeNewswire Inc.XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone PortfolioNASDAQ:XOMAXOMA Corporation
09/03/202313:45Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XOMAXOMA Corporation
09/03/202313:30GlobeNewswire Inc.XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization StrategyNASDAQ:XOMAXOMA Corporation
28/02/202313:30GlobeNewswire Inc.XOMA to Present at 43rd Annual Cowen Health Care ConferenceNASDAQ:XOMAXOMA Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XOMA

La tua Cronologia

BIT
TEN
Tenaris
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
LDO
Leonardo
BIT
MONC
Moncler
BIT
TIT
Telecom Italia
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network